Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
₹98 Cr
Revenue (TTM)
₹23 Cr
Net Profit (TTM)
₹-23 Cr
ROE
0 %
ROCE
-29.9 %
P/E Ratio
--
P/B Ratio
-0.6
Industry P/E
33.74
EV/EBITDA
-33.2
Div. Yield
0 %
Debt to Equity
-1.5
Book Value
₹-74.6
EPS
₹-10.6
Face value
10
Shares outstanding
21,560,586
CFO
₹-126.29 Cr
EBITDA
₹-147.33 Cr
Net Profit
₹-243.32 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Krebs Biochemicals
| -31.0 | -16.5 | -31.9 | -29.6 | -5.5 | -12.3 | -- |
|
BSE Healthcare
| -4.7 | -5.8 | -5.4 | 1.3 | 23.7 | 14.0 | 10.6 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Krebs Biochemicals
| -28.8 | 17.3 | -28.5 | -45.5 | 45.2 | 74.9 | -28.1 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Krebs Biochemicals
|
47.6 | 98.3 | 23.0 | -22.9 | -71.3 | -- | -- | -0.6 |
| 352.7 | 3,213.2 | 2,521.8 | 202.5 | 9.6 | 14.3 | 15.9 | 2.1 | |
| 989.6 | 12,119.0 | 2,512.3 | 543.7 | 28.3 | 19.3 | 22.3 | 3.8 | |
| 357.4 | 6,190.1 | 1,053.1 | 293.6 | 32.3 | 24.6 | 21.1 | 4.8 | |
| 1,025.1 | 10,733.1 | 1,158.7 | 309.6 | 31.9 | 17.3 | 34.3 | 5.7 | |
| 1,547.6 | 29,354.2 | 8,850.1 | 894.8 | 15.2 | 19.8 | 33.7 | 5.9 | |
| 12,433.0 | 15,953.0 | 1,575.1 | 179.1 | 14.9 | 11.4 | 89.1 | 9.6 | |
| 1,921.2 | 3,180.4 | 673.7 | 202.6 | 17.6 | 19.4 | 15.7 | 5.5 | |
| 784.3 | 3,617.1 | 588.5 | 102.9 | 22.1 | 12.7 | 35.6 | 4.3 | |
| 158.0 | 4,151.0 | 7.1 | -274.7 | -4,008.3 | -140.4 | -- | 6.2 |
No Review & Analysis are available.
Krebs Biochemicals & Industries Limited engages in the manufacture and sale of active pharmaceutical ingredients in India. The company develops biotech processes for application in medicine, agriculture, and industry. Its products include... androstenedione, lovastatin, and simvastatin, which are used for anti-cholesterol and steroid intermediate applications. The company also develops various products, including amlodipine, cetirizine, orlistat, serratiopepetidase, telmisartan, and phenylephrine for anti-hypertension, anti-histamine, anti-obesity, anti-inflammatory, and cold and cough applications. In addition, it offers contract manufacturing services for large pharmaceutical and multinational companies. Krebs Biochemicals & Industries Limited was incorporated in 1991 and is based in Visakhapatnam, India. Read more
Incorporated
1991
Chairman
R T Ravi
Managing Director
Manish Jain
Headquarters
Vishakhapatnam, Andhra Pradesh
Website
Looking for more details about Krebs Biochemicals & Industries Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
Announcements
View Announcements
The share price of Krebs Biochemicals & Industries Ltd is ₹47.63 (NSE) and ₹45.60 (BSE) as of 02-Apr-2026 IST. Krebs Biochemicals & Industries Ltd has given a return of -5.53% in the last 3 years.
Since, TTM earnings of Krebs Biochemicals & Industries Ltd is negative, P/E ratio is not available.
The P/B ratio of Krebs Biochemicals & Industries Ltd is -0.61 times as on 02-Apr-2026, a 129 discount to its peers’ median range of 2.13 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
0.00
|
-0.98
|
|
2024
|
0.00
|
-1.10
|
|
2023
|
0.00
|
-1.22
|
|
2022
|
0.00
|
-4.12
|
|
2021
|
0.00
|
-3.72
|
The 52-week high and low of Krebs Biochemicals & Industries Ltd are Rs 113.50 and Rs 38.33 as of 05-Apr-2026.
Krebs Biochemicals & Industries Ltd has a market capitalisation of ₹ 98 Cr as on 02-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Krebs Biochemicals & Industries Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
₹3.19
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.